Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: A randomized, open-label, parallel-group, flexible-dose study

International Clinical Psychopharmacology

Volumn 29, Issue 3, 2014, Pages 166-176

  Di Fiorino, Mario ^a   Montagnani, Gino ^b   Trespi, Graziella ^b   Kasper, Siegfried ^c  

^a Versilia Hospital   (Italy)

^b ASTRAZENECA   (United Kingdom)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

atypical antipsychotic; depressive symptoms; extended release; negative symptoms; quetiapine XR; risperidone; schizoaffective disorder; schizophrenia

Indexed keywords

QUETIAPINE; RISPERIDONE; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ACUTE PSYCHOSIS; ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; CALGARY DEPRESSION SCALE; COMPARATIVE EFFECTIVENESS; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DELUSION; DEPRESSION; DISORIENTATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EVENING DOSAGE; EXTRAPYRAMIDAL SYNDROME; FAINTNESS; FEMALE; HEART ARREST; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; PSYCHOTIC DISORDERS; THERAPEUTIC USE;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSION; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84897551381     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000017     Document Type: Article

References (40)

1. Addington D, Addington J, Schissel B (1990). A depression rating scale for schizophrenics. Schizophr Res 3:247-251.
2. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201-208.
3. Addington D, Addington J, Atkinson M (1996). A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 19:205-212.
4. Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al. (2011). Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry 72:75-80.
5. Alvarez E, Ciudad A, Olivares JM, Bousoño M, Gómez JC (2006). A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 26:238-249.
6. Arvanitis LA, Miller BG. the Seroquel Trial 13 study group (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246.
7. AstraZeneca (2012). Seroquel XR-summary of product characteristics for Ireland, revised 2012. Available at: http://www.medicines.ie/medicine/13032/SPC/ Seroquel + XR +50mg%2c +150mg%2c +200mg%2c + 300 mg%2c + 400mg + prolonged-release +tablets/[Accessed 18 May 2012].
8. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540-549.
9. Buckley PF (2004). Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 20:1357-1363.
10. Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009). Psychiatric comorbidities and schizophrenia. Schizophr Bull 35:383-402.
11. Calabrese JR, Keck PE Jr, MacfaddenW, Minkwitz M, Ketter TA,Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360.
12. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. (2009). Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 166:691-701.
13. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ (2007). The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 90:186-197.
14. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 70:526-539.
15. De Nayer A,Windhager E, Irmansyah , Larmo I, Lindenbauer B, Rittmannsberger H, et al. (2003). Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 7:59-66.
16. Dollfus S, Olivier V, Chabot B, Déal C, Perrin E (2005). Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 78:157-159.
17. Emsley RA, Buckley P, Jones AM, Greenwood MR (2003). Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 17:210-215.
18. Farah A (2005). Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 7:268-274.
19. Goldstein JM, Christoph G, Grimm S, Liu J, Widzowski D, Brecher M (2007). Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol 17 (Suppl 4):S401.
20. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312.
21. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. (2007). Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 68:832-842.
22. Kasper S (2004). Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 20:44-47.
23. Kelly DL, Shim JC, Feldman SM, Yu Y, Conley RR (2004). Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. J Psychiatr Res 38:531-536.
24. Kjelby E, Jørgensen HA, Kroken RA, Løberg EM, Johnsen E (2011). Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 11:145.
25. Koreen AJ, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993). Depression in first-episode schizophrenia. Am J Psychiatry 150: 1643-1648.
26. Lee KU, Jeon YW, Lee HK, Jun TY (2009). Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum Psychopharmacol 24:447-452.
27. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163-174.
28. Mullen J, Jibson MD, Sweitzer D (2001). A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23:1839-1854.
29. National Institute for Clinical Excellence 2004.). Depression management of depression in primary and secondary care. London, UK: National Institute for Clinical Excellence 2004. Available at: http://www.nice.org.uk/nicemedia/pdf/ CG023NICEguideline.pdf [Accessed 28 June 2013
30. Nyberg S, Widzowski D (2010). Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties [abstract PW01-27]. Eur Psychiatry 25 (Suppl 1):1446.
31. Reine G, Lancon C, Di Tucci S, Sapin S, Auquier P (2003). Depression and subjective quality of life in chronic phase schizophrenia patients. Acta Psychiatr Scand 108:297-303.
32. Resnick SG, Rosenheck RA, Lehman AF (2004). An exploratory analysis of correlates of recovery. Psychiatr Serv 55:540-547.
33. Roth BL, Sheffler D, Potkin SG (2003). Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res 3:108-117.
34. Seeman P (2002). Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
35. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA (2004). Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 129:141-147.
36. Siris SG (2001). Suicide and schizophrenia. J Psychopharmacol 15:127-135.
37. Siris S, Bench C (2003). Depression and schizophrenia. In: Hirsch S,Weinberger D, editors. Schizophrenia. Oxford, UK: Blackwell.
38. Small JG, Kolar MC, Kellams JJ (2004). Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin 20:1017-1023.
39. Thase M, Macfadden W, McCoy R, Chang W, Calabrese J (2006). Efficacy of quetiapine monotherapy in bipolar depression: a confirmatory double-blind, placebo-controlled study (The BOLDER II Study) [abstract P03.035]. Int J Neuropsychopharmacol 9 (Suppl 1):S237.
40. Tollefson GD, Andersen SW, Tran PV (1999). The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 46:365-373.